SUMO2 and neoplasm: The WB results demonstrated that the addition of TAK-981 led to decreased levels of SUMO1 and SUMO2/3 in primary ovarian cancer cells, increased the protein levels of PI3 and AUP1 and decreased the protein expression of CD200 and GNAS. We also performed qPCR analysis using RNA extracted from frozen tumor tissues of mice treated with TAK-981 or vehicle control.